Browsing Tag
PARADIGM Trial
5 posts
Anteris Technologies (ASX: AVR) stock up 9.6% as PARADIGM trial reaches first US patient enrolments
Edwards and Medtronic own TAVR. Anteris (ASX: AVR) wants in with DurAVR. First US PARADIGM patients enrolled, US$320m raised, and Medtronic is now a shareholder.
NeuroSense Therapeutics (NASDAQ: NRSN) advances PrimeC development after JAMA Neurology publishes PARADIGM Phase 2b ALS trial results
JAMA Neurology publishes PARADIGM trial results showing PrimeC slowed ALS decline. Discover what this means for NeuroSense Therapeutics’ Phase 3 plans.
Medtronic invests in Anteris (ASX: AVR) to fund DurAVR trial and TAVR platform expansion
Anteris Technologies has raised USD 320M, including USD 90M from Medtronic, to fund its global DurAVR heart valve trial. Read what this means for TAVR competition.
Anteris edges closer to FDA IDE approval for DurAVR PARADIGM trial after promising clinical data
Find out how Anteris’s DurAVR transcatheter heart valve is advancing toward a global pivotal trial and what it means for the structural heart market.
Anteris Technologies launches its pivotal trial phase for DurAVR THV, marking a regulatory turning point
Anteris Technologies launches the global PARADIGM pivotal trial of its DurAVR THV, challenging Edwards and Medtronic with biomimetic valve durability data—see how the race unfolds.